Table 3. The effect of IL-3, IL-5 and GM-CSF neutralization on the antiapoptotic effect of TNF-α in human eosinophils.
| Apoptosis (% of control) | |||
| Neutralizing antibody to | TNF-α (ng/ml) | IgG1 isotype control | Neutralizing antibody |
| IL-3 | 0.1 | 97±4 | 79±7 |
| 1 | 76±8 | 72±10 | |
| 10 | 83±6 | 71±12 | |
| 100 | 76±13 | 76±12 | |
| IL-5 | 0.1 | 82±3 | 85±3 |
| 1 | 75±1 | 80±11 | |
| 10 | 64±7 | 77±11 | |
| 100 | 65±8 | 77±11 | |
| GM-CSF | 0.1 | 90±4 | 93±3 |
| 1 | 85±3 | 83±5 | |
| 10 | 77±6 | 69±7 | |
| 100 | 65±4 | 66±6 | |
Eosinophils were incubated with the IgG1 isotype control or the indicated neutralizing antibody to IL-3, IL-5 or GM-CSF (each at 10 µg/ml) and various concentrations of TNF-α for 40 hours. Apoptosis was assessed by measuring the relative DNA content of propidium iodide-stained cells by flow cytometry and is expressed as percentage of control, where the corresponding value obtained in the absence of TNF-α is set as 100%. Results are means ± SEM of 5–6 independent determinations using eosinophils from different donors.